Fossil Surges 18.5% as EPS Revision Screener Flags 5 Stocks
Fossil Group (FOSL) leads today's EPS-revision winners with an 18.5% gain since detection, driven by a 664.7-percentage-point upgrade to its next-year EPS growth estimate. Alphatec (ATEC) added 16.9%, CrowdStrike (CRWD) rose 16.8% amid the AI-slowdown debate, Twist Bioscience (TWST) climbed 14.0%, and EVI Industries (EVI) advanced 11.5%. The screen's highest-conviction revision translated directly into the largest price move.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FOSL | Consumer Cyclical | 2026-09-10 | +664.7pp | +18.5% |
| ATEC | Healthcare | 2026-09-09 | N/A | +16.9% |
| CRWD | Technology | 2026-09-13 | N/A | +16.8% |
| TWST | Healthcare | 2026-09-09 | +1.5pp | +14.0% |
| EVI | Industrials | 2026-09-10 | N/A | +11.5% |
Why did FOSL stock jump in September 2026?
FOSL jumped 18.5% (from $4.49 to $5.32) after the EPS revision screener detected its next-year growth estimate rising from 111.5% to 776.2% on September 10, 2026.
The 664.7-percentage-point revision is the largest of any stock flagged in this run and occurred without an accompanying earnings-related news item, meaning pre-earnings positioning and analyst estimate momentum drove the move. Fossil's revised growth estimate reflects the sharp cyclical recovery in consumer discretionary names that have been rebuilding earnings off a depressed base. The screen caught the revision at $4.49, and the market confirmed it with five sessions of buying pressure that pushed the stock to $5.32 by September 16.
FOSL EPS revision history → · Screener snapshot from 2026-09-10 →
Why did ATEC stock jump in September 2026?
ATEC jumped 16.9% (from $8.98 to $10.50) after the EPS revision screener flagged its 86.6% next-year EPS growth estimate on September 9, 2026.
No earnings-specific news was published in the window, so the gain reflects broader accumulation in the medical-device sector, where Alphatec's spine-implant growth trajectory stands out for its high revision rate. The stock was detected near $8.98 and climbed to $10.50 over five sessions, a move that tracks the healthcare sector's rotation into higher-growth small- and mid-cap names. The screener's early read on ATEC allowed detection before the full 16.9% move played out.
ATEC EPS revision history → · Screener snapshot from 2026-09-09 →
Why did CRWD stock jump in September 2026?
CRWD jumped 16.8% (from $206.74 to $241.36) after the EPS screener flagged its 27.5% next-year EPS growth estimate on September 13, 2026.
The gain coincided with CrowdStrike CEO George Kurtz joining Nvidia and Broadcom in dismissing the AI slowdown debate, arguing that increasingly capable AI models expand the attack surface and, by extension, cybersecurity demand. That public stance on September 14 reinforced the earnings-based signal, helping the stock add $34.62 in three sessions, from $206.74 to $241.36. CrowdStrike's 27.5% growth estimate and its position as the largest-cap name on this list gave the move additional credibility with institutional buyers.
CRWD EPS revision history → · Screener snapshot from 2026-09-13 →
Why did TWST stock jump in September 2026?
TWST jumped 14.0% (from $125.52 to $143.07) after the EPS revision screener detected a modest upgrade to its next-year growth estimate, from 35.1% to 36.6%, on September 9, 2026.
The 1.5-percentage-point revision was the smallest of the five flagged stocks, yet Twist Bioscience still delivered the fourth-largest gain, showing that even small upward revisions can precede outsized moves when sentiment is already improving. No earnings-related news appeared in the window, leaving the synthetic-biology sector's broader rebound as the contextual driver. The stock added $17.55 per share between detection and September 16, with the move broadening beyond the initial revision signal.
TWST EPS revision history → · Screener snapshot from 2026-09-09 →
Why did EVI stock jump in September 2026?
EVI jumped 11.5% (from $15.45 to $17.23) after the EPS revision screener identified its 29.9% next-year EPS growth estimate on September 10, 2026.
No earnings news was released during the window, which points to the industrial-distribution sector's steady margin recovery as the underlying support for the move. EVI's high base growth rate placed it among the screen's stronger candidates, and the stock responded with a six-session climb of $1.78. The move demonstrates that even without a discrete catalyst, an upward estimate revision can attract momentum capital into small-cap industrials.
EVI EPS revision history → · Screener snapshot from 2026-09-10 →
Today's leaders show that the size of the EPS estimate revision still matters most — Fossil's 664.7pp upgrade produced the largest gain, while the smallest revision (Twist's 1.5pp) still yielded 14.0%. The mix of consumer, healthcare, technology, and industrial names signals broad-based estimate momentum rather than a single-sector rally.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →